Fred Hutch Cancer Center | Association Partnerships

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

Clinical experiences with belusmosudil are shared among the panel.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

The group discusses treatment goals and patient education for chronic GVHD.

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

Discussing findings from a phase 1/2 study, Sarah P. Psutka MD, looks at the use of acupuncture for patients with non muscle-invasive bladder cancer prior to induction of their BCG treatment.

The panelists share their insights on the identification of patients at high risk for GVHD.

Dr Chen presents statistics on the incidence of chronic graft versus host disease.

Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.

A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.

Mazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.

Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.

Showing similarity to results from CheckMate 214, findings from CheckMate 920 shows that nivolumab plus ipilimumab can safety be administered to patients with non-clear cell renal cell carcinoma.

Idecabtagene vicleucel is now an available treatment option for some patients with relapsed or refractory multiple myeloma who are being treated at Seattle Cancer Care Alliance.